Thorac Cardiovasc Surg 1983; 31: 57-58
DOI: 10.1055/s-2007-1022029
© Georg Thieme Verlag Stuttgart · New York

Clinical Results of the Aortic Medtronic-Hall Prosthesis

C. Vaislic, G. Servet, J. Tasrini, A. Cerene
  • Department of Cardiovascular Surgery and Angiology, Rangueil Hospital, Toulouse, France
Further Information

Publication History

Publication Date:
19 March 2008 (online)

Summary

Between July 1979 and June 1982 we implanted aortic Medtronic-Hall prostheses in 40 patients. Ages ranged between 25 and 75, with a mean of 56 years. There were 38 cases of elective surgery (group I ) and 2 acute aortic dissections (group II). All patients received anticoagulant medication.

Follow-up ranged between 8 and 39 months with a mean of 22.5 months. Excluding operative mortality (7.5%) the 2-year actuarial survival rate is 97.2 %. No death was related to the valve or its dysfunction.

The overall thromboembolic rate is 0.78 per 100 patient years. No thromboembolic episode occurred in group I. No hemolysis was encountered and most patients experienced marked postoperative improvement.

We consider that aortic Medtronic-Hall valves are valuable but further studies are necessary to confirm the results we obtained.